Cambridge biotech Healx stands on the cusp of history after dosing the first patient with a rare and deadly cancer with a ...
Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 trial evaluating the safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback